Precigen, Inc. (NASDAQ:PGEN) reported mixed results for the fourth quarter on Wednesday.
The company posted a quarterly loss of 1 cent per share which beat the analyst consensus estimate of losses of 8 cents per share. The company reported quarterly sales of $4.565 million which missed the analyst consensus estimate of $8.286 million.
“With the FDA approval and launch of PAPZIMEOS, 2025 marked a transformational year for Precigen as we transitioned from a clinical-stage to a commercial-stage company and recognized our first commercial product revenues toward the end of the year,” said Helen Sabzevari, PhD, President and CEO of Precigen. “We are seeing strong alignment within the physician community around PAPZIMEOS as the first-line standard of care for adults …
This post was originally published here
